Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)
- Authors:
- Huijuan Chen
- Qiming Zhou
-
Affiliations: Computer Network Information Center, Chinese Academy of Sciences, Beijing 100190, P.R. China, ChosenMed Clinical Laboratory (Beijing) Co., Ltd., Beijing 100176, P.R. China - Published online on: April 12, 2023 https://doi.org/10.3892/or.2023.8543
- Article Number: 106
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, Xu Y, Shao Y, et al: Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 12:6770–6780. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Ma ZL, Li B, Pan YJ, Xiang JQ, Zhang YW, Sun YH, Hou T, Lizaso A, Chen Y, et al: Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients. Cancer Med. 10:8377–8386. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, et al: Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7:1394–1403. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, Rundell V, Wulff J, Sharma G, Knock H, et al: Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 33:500–510. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, et al: Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 30:1804–1812. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gögenur M, Hadi NA, Qvortrup C, Andersen CL and Gögenur I: ctDNA for risk of recurrence assessment in patients treated with neoadjuvant treatment: A systematic review and meta-analysis. Ann Surg Oncol. 29:8666–8674. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cullinane C, Fleming C, O'Leary DP, Hassan F, Kelly L, O'Sullivan MJ, Corrigan MA and Redmond HP: Association of circulating tumor DNA with disease-free survival in breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 3:e20269212020. View Article : Google Scholar : PubMed/NCBI | |
|
Pantel K and Alix-Panabières C: Liquid biopsy and minimal residual disease-latest advances and implications for cure. Nat Rev Clin Oncol. 16:409–424. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Heitzer E, Haque IS, Roberts CES and Speicher MR: Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5:1124–1131. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, Ji L, Chen Y, Zhao Y, Qian F, et al: Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 11:346–354. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
MandeL P and Metais P: Les acides nucléiques du plasma sanguin chez l'homme (Nuclear Acids in Human Blood Plasma). C R Seances Soc Biol Fil. 142:241–243. 1948.(In French). PubMed/NCBI | |
|
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665. 2001.PubMed/NCBI | |
|
Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, et al: Double-stranded DNA in exosomes: A novel biomarker in cancer detection. Cell Res. 24:766–779. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, Azad TD, Dudley JC and Chaudhuri AA: Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA). Mol Diagn Ther. 23:311–331. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei F, Lin CC, Joon A, Feng Z, Troche G, Lira ME, Chia D, Mao M, Ho CL, Su WC, et al: Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med. 190:1117–1126. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri AA, Stehr H, et al: Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 9:500–509. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, et al: Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 6:88392015. View Article : Google Scholar : PubMed/NCBI | |
|
Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, et al: Cell-free DNA from ascites and pleural effusions: Molecular insights into genomic aberrations and disease biology. Mol Cancer Ther. 16:948–955. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang P and Lo Y MD: The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. 32:360–371. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yao W, Mei C, Nan X and Hui L: Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. Gene. 590:142–148. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lo YM, Zhang J, Leung TN, Lau TK, Chang AM and Hjelm NM: Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 64:218–224. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wong FC, Sun K, Jiang P, Cheng YK, Chan KC, Leung TY, Chiu RW and Lo YM: Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clin Biochem. 49:1379–1386. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lam WKJ, Gai W, Sun K, Wong RSM, Chan RWY, Jiang P, Chan NPH, Hui WWI, Chan AWH, Szeto CC, et al: DNA of erythroid origin is present in human plasma and informs the types of anemia. Clin Chem. 63:1614–1623. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, et al: High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 25:1928–1937. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Breitbach S, Tug S, Helmig S, Zahn D, Kubiak T, Michal M, Gori T, Ehlert T, Beiter T and Simon P: Direct quantification of cell-free, circulating DNA from unpurified plasma. PLoS One. 9:e878382014. View Article : Google Scholar : PubMed/NCBI | |
|
Tug S, Helmig S, Deichmann ER, Schmeier-Jürchott A, Wagner E, Zimmermann T, Radsak M, Giacca M and Simon P: Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 21:164–173. 2015.PubMed/NCBI | |
|
Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Redman CW and Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet. 350:485–487. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–450. 1977.PubMed/NCBI | |
|
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46:318–322. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med. 14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H, Wei W, Ye Z, Zheng J and Xu RH: Liquid biopsy of methylation biomarkers in cell-free DNA. Trends Mol Med. 27:482–500. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP and Shendure J: Fragment length of circulating tumor DNA. PLoS Genet. 12:e10061622016. View Article : Google Scholar : PubMed/NCBI | |
|
Dressman D, Yan H, Traverso G, Kinzler KW and Vogelstein B: Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA. 100:8817–8822. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al: Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5:1710–1717. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, et al: Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 39:1537–1547. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
McDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, Kim DW, Lennerz JK, Hazar-Rethinam M, Van Seventer EE, Fetter IJ, et al: Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer. JCO Precis Oncol. 5:PO.20.00220. 2021.PubMed/NCBI | |
|
Guerrini F, Paolicchi M, Ghio F, Ciabatti E, Grassi S, Salehzadeh S, Ercolano G, Metelli MR, Del Re M, Iovino L, et al: The droplet digital PCR: A new valid molecular approach for the assessment of B-RAF V600E mutation in hairy cell leukemia. Front Pharmacol. 7:3632016. View Article : Google Scholar : PubMed/NCBI | |
|
Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A and Ibarrola-Villava M: Circulating tumor DNA detection by digital-droplet PCR in pancreatic ductal adenocarcinoma: A systematic review. Cancers (Basel). 13:9942021. View Article : Google Scholar : PubMed/NCBI | |
|
Elazezy M and Joosse SA: Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 16:370–378. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, et al: False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 24:4437–4443. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Abbosh C, Swanton C and Birkbak NJ: Clonal haematopoiesis: A source of biological noise in cell-free DNA analyses. Ann Oncol. 30:358–359. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Flach S, Howarth K, Hackinger S, Pipinikas C, Ellis P, McLay K, Marsico G, Forshew T, Walz C, Reichel CA, et al: Liquid BIOpsy for MiNimal RESidual DiSease Detection in head and neck squamous cell carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer. 126:1186–1195. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, et al: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 11:eaax73922019. View Article : Google Scholar : PubMed/NCBI | |
|
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al: Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 32:229–239. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Loomis B, Ishii J, Wolchok JD, Boland G, Robine N, Altorki NK and Landau DA: Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 26:1114–1124. 2020. View Article : Google Scholar | |
|
Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, Ruiz-Valdepenas A, Santonja A, Morris J, Chandrananda D, et al: ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Transl Med. 12:eaaz80842020. View Article : Google Scholar : PubMed/NCBI | |
|
Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, et al: Impact of circulating tumor DNA-Based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol. 6:e21001812022. View Article : Google Scholar : PubMed/NCBI | |
|
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, et al: Phylo genetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 545:446–451. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, et al: Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 7:1034–1047. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 23:703–713. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Honoré N, Galot R, van Marcke C, Limaye N and Machiels JP: Liquid biopsy to detect minimal residual disease: Methodology and impact. Cancers (Basel). 13:53642021. View Article : Google Scholar : PubMed/NCBI | |
|
Deveson IW, Gong B, Lai K, LoCoco JS, Richmond TA, Schageman J, Zhang Z, Novoradovskaya N, Willey JC, Jones W, et al: Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 39:1115–1128. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stahlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L and Godfrey TE: Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. Nat Protoc. 12:664–682. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tewhey R, Warner JB, Nakano M, Libby B, Medkova M, David PH, Kotsopoulos SK, Samuels ML, Hutchison JB, Larson JW, et al: Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol. 27:1025–1031. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dudley JC and Diehn M: Detection and diagnostic utilization of cellular and cell-free tumor DNA. Annu Rev Pathol. 16:199–222. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, et al: Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 27:5586–5594. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sethi H, Salari R, Navarro S, Natarajan P, Srinivasan R, Dashner S, Tin T, Balcioglu M, Swenerton R and Zimmermann B: Abstract 4542: Analytical validation of the SignateraTM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay. Cancer Res. 78:45422018. View Article : Google Scholar | |
|
Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, et al: Early detection of metastatic relapse and monitoring of therapeutic efficacy by Ultra-Deep sequencing of plasma cell-Free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 37:1547–1557. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al: Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, et al: Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 25:4255–4263. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, et al: Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 40:2408–2419. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li R, Bonora G, Dai C, Xiang B, Zheng T, Mo W, Wang X, Zhou K, Jia S, Luo S, et al: 911P the development and application of a baseline-agnostic minimal residual disease assay. Ann Oncol. 33:S9642022. View Article : Google Scholar | |
|
Pellini B, Pejovic N, Feng W, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Petty M, et al: ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. JCO Precis Oncol. 5:PO.20.00276. 2021.PubMed/NCBI | |
|
Abbosh C, Frankell A, Garnett A, Harrison T, Weichert M, Licon A, Veeriah S, Daber B, Moreau M, Chesh A, et al: Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. Cancer Res. 80:CT0232020. View Article : Google Scholar | |
|
Peng M, Huang Q, Yin W, Tan S, Chen C, Liu W, Tang J, Wang X, Zhang B, Zou M, et al: Circulating tumor DNA as a prognostic biomarker in localized Non-small Cell lung cancer. Front Oncol. 10:5615982020. View Article : Google Scholar : PubMed/NCBI | |
|
Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, et al: Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res. 25:4973–4984. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Duineveld LA, van Asselt KM, Bemelman WA, Smits AB, Tanis PJ, van Weert HC and Wind J: Symptomatic and asymptomatic colon cancer recurrence: A multicenter cohort study. Ann Fam Med. 14:215–220. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, et al: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 8:346ra922016. View Article : Google Scholar : PubMed/NCBI | |
|
Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, Wong HL, Kosmider S, Wong R, Thomson B, et al: Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Med. 18:e10036202021. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al: Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 7:302ra13322015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD and Radovich M: Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer. 3:242017. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, et al: Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5:1473–1478. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, et al: Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res. 26:2556–2564. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, et al: Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 158:494–505. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, Guo Y, Yi X, Yang L and Huang D: Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer. Front Oncol. 10:12202020. View Article : Google Scholar : PubMed/NCBI | |
|
Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, Broeckaert MAM, Anagnostou V, Adleff V, Bruhm DC, et al: White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 11:5252020. View Article : Google Scholar : PubMed/NCBI | |
|
Hilke FJ, Muyas F, Admard J, Kootz B, Nann D, Welz S, Rieß O, Zips D, Ossowski S, Schroeder C and Clasen K: Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemo therapy. Radiother Oncol. 151:182–189. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, et al: Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 30:804–814. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moding EJ, Nabet BY, Alizadeh AA and Diehn M: Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 11:2968–2986. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, et al: ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann Oncol. 33:750–768. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Andersson D, Kristiansson H, Kubista M and Stahlberg A: Ultrasensitive circulating tumor DNA analysis enables precision medicine: Experimental workflow considerations. Expert Rev Mol Diagn. 21:299–310. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nikolaev S, Lemmens L, Koessler T, Blouin JL and Nouspikel T: Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 542:34–39. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ungerer V, Bronkhorst AJ and Holdenrieder S: Preanalytical variables that affect the outcome of cell-free DNA measurements. Crit Rev Clin Lab Sci. 57:484–507. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Risberg B, Tsui DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass F, et al: Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients. J Mol Diagn. 20:883–892. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu RW, Lui WB, El-Sheikhah A, Chan AT, Lau TK, Nicolaides KH and Lo YM: Comparison of protocols for extracting circulating DNA and RNA from maternal plasma. Clin Chem. 51:2209–2210. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, et al: Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 28:1325–1332. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, Lee M, Wong R, Kosmider S, Skinner I, et al: Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. Int J Cancer. 148:1014–1026. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Abbosh C, Birkbak NJ and Swanton C: Early stage NSCLC-challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 15:577–586. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, et al: Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing. Clin Chem. 64:1626–1635. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, et al: Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 52:1219–1226. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, et al: Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 21:374–382. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, et al: Integrating genomic features for non-invasive early lung cancer detection. Nature. 580:245–251. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, Zevallos JP, Davis AA, Pellini B and Chaudhuri AA: Commercial ctDNA assays for minimal residual disease detection of solid tumors. Mol Diagn Ther. 25:757–774. 2021. View Article : Google Scholar : PubMed/NCBI |
